Literature DB >> 19643060

Pandemic influenza A(H1N1)v viruses currently circulating in New Zealand are sensitive to oseltamivir.

R J Hall1, M P Peacey, J C Ralston, J Bocacao, M Ziki, W Gunn, A Quirk, Q S Huang.   

Abstract

New Zealand, like other southern hemisphere countries with a temperate climate, has been in the winter period with seasonal influenza activity. New Zealand has also experienced a dramatic increase in the number of cases of pandemic influenza A(H1N1)v virus. Early reports from the northern hemisphere at the beginning of the pandemic showed that the virus was sensitive to the antiviral drug oseltamivir. In this study we report that pandemic influenza A(H1N1)v viruses currently circulating in New Zealand are sensitive to oseltamivir, but seasonal influenza A(H1N1) viruses - the co-circulating predominant seasonal strain, is resistant to oseltamivir.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19643060     DOI: 10.2807/ese.14.30.19282-en

Source DB:  PubMed          Journal:  Euro Surveill        ISSN: 1025-496X


  12 in total

1.  Pandemic Seasonal H1N1 Reassortants Recovered from Patient Material Display a Phenotype Similar to That of the Seasonal Parent.

Authors:  Stephanie Sonnberg; Mariette F Ducatez; Jennifer DeBeauchamp; Jeri-Carol Crumpton; Adam Rubrum; Bridgett Sharp; Richard J Hall; Matthew Peacey; Sue Huang; Richard J Webby
Journal:  J Virol       Date:  2016-08-12       Impact factor: 5.103

2.  Synergistic combinations of favipiravir and oseltamivir against wild-type pandemic and oseltamivir-resistant influenza A virus infections in mice.

Authors:  Donald F Smee; E Bart Tarbet; Yousuke Furuta; John D Morrey; Dale L Barnard
Journal:  Future Virol       Date:  2013-11       Impact factor: 1.831

3.  Combinations of favipiravir and peramivir for the treatment of pandemic influenza A/California/04/2009 (H1N1) virus infections in mice.

Authors:  E Bart Tarbet; Masako Maekawa; Yousuke Furuta; Y S Babu; John D Morrey; Donald F Smee
Journal:  Antiviral Res       Date:  2012-03-10       Impact factor: 5.970

4.  Genotyping assay for the identification of 2009-2010 pandemic and seasonal H1N1 influenza virus reassortants.

Authors:  M F Ducatez; S Sonnberg; R J Hall; M Peacey; J Ralston; R J Webby; Q S Huang
Journal:  J Virol Methods       Date:  2010-05-05       Impact factor: 2.014

5.  Tracking oseltamivir-resistance in New Zealand influenza viruses during a medicine reclassification in 2007, a resistant-virus importation in 2008 and the 2009 pandemic.

Authors:  Richard J Hall; Matthew Peacey; Jacqui C Ralston; Danielle J de Joux; Judy Bocacao; Mackenzie Nicol; Molly Ziki; Wendy Gunn; Jing Wang; Q Sue Huang
Journal:  Western Pac Surveill Response J       Date:  2012-10-30

6.  Understanding the Influenza A H1N1 2009 Pandemic.

Authors:  Zakariya Al-Muharrmi
Journal:  Sultan Qaboos Univ Med J       Date:  2010-07-19

7.  Antiviral susceptibility of avian and swine influenza virus of the N1 neuraminidase subtype.

Authors:  Terri D Stoner; Scott Krauss; Rebecca M DuBois; Nicholas J Negovetich; David E Stallknecht; Dennis A Senne; Marie R Gramer; Seth Swafford; Tom DeLiberto; Elena A Govorkova; Robert G Webster
Journal:  J Virol       Date:  2010-07-21       Impact factor: 5.103

8.  Demographic Determinants of Influenza Vaccination and Infection, Brazos County, Texas, 2017.

Authors:  Yao Akpalu; Ibraheem Karaye; Julie Anderson; Osaro Mgbere; Jennifer A Horney
Journal:  Infect Dis (Auckl)       Date:  2019-07-15

9.  Shedding of the Pandemic Swine-Origin Influenza A Virus (H1N1) after Oseltamivir Administration.

Authors:  Leiyun Weng; Qiang Wang; Wei Wang; Peijun Ren; Vincent Deubel; Tetsuya Toyoda
Journal:  Influenza Res Treat       Date:  2010-12-14

10.  Pandemic (H1N1) 2009 and seasonal influenza A (H1N1) co-infection, New Zealand, 2009.

Authors:  Matthew Peacey; Richard J Hall; Stephanie Sonnberg; Mariette Ducatez; Shevaun Paine; Mackenzie Nicol; Jacqui C Ralston; Don Bandaranayake; Virginia Hope; Richard J Webby; Sue Huang
Journal:  Emerg Infect Dis       Date:  2010-10       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.